Document Detail

Antiarrhythmic properties of ranolazine--from bench to bedside.
MedLine Citation:
PMID:  22916846     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Pharmacological management of cardiac arrhythmias is limited by the reduced availability of safe and effective antiarrhythmic agents.
AREAS COVERED: Ranolazine is an agent currently used for the treatment of angina, which inhibits transmembrane ionic currents involved in several phases of the action potential in both the atrial and the ventricular cells. Due to its mechanism of action, ranolazine has been shown to exhibit antiarrhythmic properties that have been validated in the experimental models. This article recapitulates the mechanism of antiarrhythmic action of ranolazine, the existing clinical data, and the ongoing relevant clinical trials.
EXPERT OPINION: The combination of the antiischemic properties of ranolazine with its antiarrhythmic potency and minimal proarrhythmia provides a promising background that could expand its therapeutic role in the management of atrial fibrillation and ventricular tachyarrhythmias. Data derived from adequately powered randomized clinical trials will determine whether the door to a new indication will open for ranolazine in the near future.
Stylianos Tzeis; George Andrikopoulos
Related Documents :
484496 - Quantification of thallium-201 scintigrams in acute myocardial infarction.
2031876 - Effect of propionyl-l-carnitine on experimental myocardial infarction in dogs.
1449296 - Effect of delay in retroperfusion therapy on infarct size reduction.
21874556 - Determination of the myocardial area at risk with pre- versus post-reperfusion imaging ...
2707276 - Right heart failure due to an inter-atrial shunt after percutaneous mitral balloon dila...
10155176 - Medical therapy of acute myocardial infarction: part ii. the role of adjunctive medical...
Publication Detail:
Type:  Journal Article     Date:  2012-08-23
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  21     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-12     Completed Date:  2013-03-08     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1733-41     Citation Subset:  IM    
Henry Dunant Hospital, Cardiology Department, Stylianos Tzeis MD, 107, Mesogion str, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / adverse effects,  pharmacology*,  therapeutic use
Anti-Arrhythmia Agents / adverse effects,  pharmacology*,  therapeutic use
Arrhythmias, Cardiac / drug therapy*,  physiopathology
Atrial Fibrillation / drug therapy,  physiopathology
Clinical Trials as Topic
Piperazines / adverse effects,  pharmacology*,  therapeutic use
Tachycardia, Ventricular / drug therapy,  physiopathology
Reg. No./Substance:
0/Acetanilides; 0/Anti-Arrhythmia Agents; 0/Piperazines; 110445-25-5/ranolazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Theoretical Investigation of Selenium Interferences in Inductively Coupled Plasma Mass Spectrometry.
Next Document:  Field Epidemiology and Laboratory Training Programs in West Africa as a model for sustainable partne...